CI

CeriBell, Inc.

CBLL·NASDAQ

$17.18

-1.8%
HealthcareMedical - Devices

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.

At a Glance

Live Snapshot
Market Cap$651.86M
EPS-1.4600
P/E Ratio-11.77
Earnings Date08/04/2026

No Dividend Yield Data

CBLL has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

CBLL has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

CBLL has not reported any net dividends paid values in the available annual periods.

CI

CeriBell, Inc. Dividend History

CBLL · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

CBLL Dividend Payment History

CBLL · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
c

CeriBell, Inc. Payout Ratio Analysis

CBLL · NASDAQ
Dividends Paid
0.00
2025
Net Income
-53.41M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.